Humana (NYSE:HUM) shares have surged approximately 48% over the past month, significantly outperforming peers UnitedHealth Group (UNH) and Cigna Group (CI). The rally is primarily driven by a favorable Medicare Advantage rate decision that lifted regulatory overhangs, combined with strong Q1 2026 financial results. Humana reported adjusted earnings per share of $10.31, beating the consensus estimate of $10.20, while revenue increased 24% year-over-year to $39.65 billion. The company's insurance segment benefit ratio improved to 89%, surpassing internal guidance, and individual Medicare Advantage membership grew by 22% year-to-date. Management has affirmed full-year 2026 adjusted EPS guidance of at least $9 and revenue of at least $160 billion. CEO Jim Rechtin highlighted a solid start to the year, noting that operating execution is well-positioned for future growth. Despite the strong momentum, analysts note that much of the regulatory relief may already be priced into the stock, with some suggesting Humana could be overvalued by 16% relative to a fair value near $213. The stock recently consolidated between $293 and $304 after opening at $301.11, indicating a potential pause in the rally as investors digest the magnitude of the recent gains. Key upcoming catalysts include the October Stars ratings release and enrollment commentary, which will be critical for sustaining the recovery narrative. While operating cash flow surged 279% year-over-year to $1.254 billion in Q1, the long-term context shows Humana is still down 32% over the past five years, framing the current move as a significant recovery rally rather than the start of a new bull market.